AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities. On this page we provide an overview of what we are doing to support the COVID-19 response.
Peer-reviewed primary analysis of Phase III trials with AstraZeneca’s Covid-19 vaccine published
AZD1222 Oxford Phase III trials interim analysis results published in The Lancet
AstraZeneca concludes agreement for supply of AZD1222 COVID-19 vaccine to Switzerland
AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit